🚀 VC round data is live in beta, check it out!
Suraksha Diagnostics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Suraksha Diagnostics and similar public comparables like BICO Group, Centrum Medyczne ENEL-MED, Atlantic International, Concord Medical and more.
Suraksha Diagnostics Overview
About Suraksha Diagnostics
Suraksha Diagnostic Ltd offers a one-stop integrated solution for pathology and radiology testing, and medical consultation services to its customers through its extensive operational network, consisting of its flagship central reference laboratory, satellite laboratories, and customer touchpoints which include diagnostic centres and sample collection centres across the states of West Bengal, Bihar, Assam, and Meghalaya.
Founded
2005
HQ
Employees
1.3K
Website
Financials (LTM)
EV
$167M
Suraksha Diagnostics Financials
Suraksha Diagnostics reported last 12-month revenue of $33M and EBITDA of $10M.
In the same LTM period, Suraksha Diagnostics generated $30M in gross profit, $10M in EBITDA, and $3M in net income.
Revenue (LTM)
Suraksha Diagnostics P&L
In the most recent fiscal year, Suraksha Diagnostics reported revenue of $30M and EBITDA of $9M.
Suraksha Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $33M | XXX | $30M | XXX | XXX | XXX |
| Gross Profit | $30M | XXX | $24M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 81% | XXX | XXX | XXX |
| EBITDA | $10M | XXX | $9M | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 32% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $3M | XXX | $4M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | — | — | $386K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Suraksha Diagnostics Stock Performance
Suraksha Diagnostics has current market cap of $159M, and enterprise value of $167M.
Market Cap Evolution
Suraksha Diagnostics' stock price is $3.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $167M | $159M | 0.5% | XXX | XXX | XXX | $0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSuraksha Diagnostics Valuation Multiples
Suraksha Diagnostics trades at 5.1x EV/Revenue multiple, and 16.3x EV/EBITDA.
EV / Revenue (LTM)
Suraksha Diagnostics Financial Valuation Multiples
As of April 19, 2026, Suraksha Diagnostics has market cap of $159M and EV of $167M.
Equity research analysts estimate Suraksha Diagnostics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Suraksha Diagnostics has a P/E ratio of 45.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $159M | XXX | $159M | XXX | XXX | XXX |
| EV (current) | $167M | XXX | $167M | XXX | XXX | XXX |
| EV/Revenue | 5.1x | XXX | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | 16.3x | XXX | 17.6x | XXX | XXX | XXX |
| EV/EBIT | 29.5x | XXX | 31.0x | XXX | XXX | XXX |
| EV/Gross Profit | 5.6x | XXX | 6.9x | XXX | XXX | XXX |
| P/E | 45.4x | XXX | 43.8x | XXX | XXX | XXX |
| EV/FCF | 170.2x | XXX | 51.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Suraksha Diagnostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Suraksha Diagnostics Margins & Growth Rates
Suraksha Diagnostics' revenue in the last 12 month grew by 19%.
Suraksha Diagnostics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.
Suraksha Diagnostics' rule of 40 is 51% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Suraksha Diagnostics' rule of X is 80% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Suraksha Diagnostics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 51% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 80% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 63% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Suraksha Diagnostics Public Comps
See public comps and valuation multiples for other Hospitals & Clinics and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Suraksha Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| BICO Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Centrum Medyczne ENEL-MED | XXX | XXX | XXX | XXX | XXX | XXX |
| Atlantic International | XXX | XXX | XXX | XXX | XXX | XXX |
| Concord Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Limes Schlosskliniken | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Suraksha Diagnostics M&A Activity
Suraksha Diagnostics acquired XXX companies to date.
Last acquisition by Suraksha Diagnostics was on XXXXXXXX, XXXXX. Suraksha Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Suraksha Diagnostics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSuraksha Diagnostics Investment Activity
Suraksha Diagnostics invested in XXX companies to date.
Suraksha Diagnostics made its latest investment on XXXXXXXX, XXXXX. Suraksha Diagnostics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Suraksha Diagnostics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Suraksha Diagnostics
| When was Suraksha Diagnostics founded? | Suraksha Diagnostics was founded in 2005. |
| Where is Suraksha Diagnostics headquartered? | Suraksha Diagnostics is headquartered in India. |
| How many employees does Suraksha Diagnostics have? | As of today, Suraksha Diagnostics has over 1K employees. |
| Is Suraksha Diagnostics publicly listed? | Yes, Suraksha Diagnostics is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Suraksha Diagnostics? | Suraksha Diagnostics trades under SURAKSHA ticker. |
| When did Suraksha Diagnostics go public? | Suraksha Diagnostics went public in 2024. |
| Who are competitors of Suraksha Diagnostics? | Suraksha Diagnostics main competitors are BICO Group, Centrum Medyczne ENEL-MED, Atlantic International, Concord Medical. |
| What is the current market cap of Suraksha Diagnostics? | Suraksha Diagnostics' current market cap is $159M. |
| What is the current revenue of Suraksha Diagnostics? | Suraksha Diagnostics' last 12 months revenue is $33M. |
| What is the current revenue growth of Suraksha Diagnostics? | Suraksha Diagnostics revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of Suraksha Diagnostics? | Current revenue multiple of Suraksha Diagnostics is 5.1x. |
| Is Suraksha Diagnostics profitable? | Yes, Suraksha Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Suraksha Diagnostics? | Suraksha Diagnostics' last 12 months EBITDA is $10M. |
| What is Suraksha Diagnostics' EBITDA margin? | Suraksha Diagnostics' last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Suraksha Diagnostics? | Current EBITDA multiple of Suraksha Diagnostics is 16.3x. |
| What is the current FCF of Suraksha Diagnostics? | Suraksha Diagnostics' last 12 months FCF is $980K. |
| What is Suraksha Diagnostics' FCF margin? | Suraksha Diagnostics' last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Suraksha Diagnostics? | Current FCF multiple of Suraksha Diagnostics is 170.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.